Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023
- Carisma is giving an oral presentation during the meeting:
Chris Sloas, Ph.D., Senior Scientist, Carisma Therapeutics will give a presentation titled "Engineered Microenvironment Converters (EM-Cs): Macrophages Expressing Synthetic Cytokine Receptors Rebalance Pro-/Anti-Inflammatory Signals in Disease Microenvironments" Friday, May 19, 2023at 5:15 pm PST
- Carisma will also present two abstracts during the meeting:
- Pre-clinical development of CT-1119, a mesothelin-targeting chimeric antigen receptor macrophage poster
- A Phase 1, First in Human (FIH) Study of Autologous Anti-HER2 Chimeric Antigen Receptor Macrophage (CAR-M) in Participants(pt) with HER2 Overexpressing Solid Tumors Trials in Progress Poster
Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation titled "Beyond T-cells: CAR-Macs, CAR-NKs." Tuesday, May 16, 2023at 10:45 am PST Tuesday, May 16to Saturday, May 20, 2023 Los Angeles, California
Nicholas Minutolo, Ph.D., Head of Protein Engineering, will give a presentation titled "Advances in CAR-M Cellular Immunotherapy" during the meeting. Wednesday, May 17, 2023at 3:05 pm EDT Boston, Massachusetts
Myeloid Network Seminar Series
Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer, will give a presentation titled "Genetically engineering macrophages: CAR-M and Beyond." Thursday, May 11, 2023at 11:00 am EDT
A replay of webcasts, when available, will be posted and archived at Carisma's Investor Events webpage for a limited time following the event.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma in future healthcare industry and investor conferences. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-may-2023-301817436.html